Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs
Research output: Contribution to journal › Journal article › Research › peer-review
Experimental "vascular" headache in humans may be used in characterizing new migraine drugs. The effects of sumatriptan on nitroglycerin-(NTG)-induced headache and arterial responses were therefore studied. Following a double-blind randomized crossover design, 10 healthy volunteers received sumatriptan 6 mg s.c. or placebo succeeded by 20 min NTG (0.12 microgram/kg/min) infusion. Headache was rated on a 10 points scale. Temporal and radial artery diameters and velocity in the middle cerebral artery (MCA) were measured with ultrasound. Sumatriptan reduced the NTG-induced headache, median score 1.5 versus 4 after placebo (p < 0.01) and decreased temporal and radial artery diameters 75 +/- 3 and 86 +/- 3% of baseline respectively (p < 0.05). Blood velocity in the MCA was unaffected. The NTG model may prove to be a valuable tool in the development of future migraine drugs. The results suggest that NTG headache in non-migraineurs may share mechanisms with migraine headache.
|Journal||Cephalalgia : an international journal of headache|
|Number of pages||7|
|Publication status||Published - Oct 1996|
- Adult, Blood Flow Velocity, Brain, Cross-Over Studies, Double-Blind Method, Female, Headache, Humans, Male, Nitric Oxide, Nitric Oxide Synthase, Nitroglycerin, Sumatriptan, Vascular Resistance, Vasoconstrictor Agents, Vasodilator Agents